---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Chembio Diagnostics, Inc.

---

(Name of Issuer)

Common Stock, $0.01 par value

---

(Title of Class of Securities)

163572100

---

Cusip Number

Norman H. Pessin

366 Madison Avenue, 14^th Floor

New York, NY  10017

212-661-2670

---

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

September 20, 2013

---

(Date of Event which Requires Filing

of this Statement)

If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

---

---

PAGE 2

CUSIP No. 163572100

Schedule 13D

1	NAME OF REPORTING PERSON
	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
	SEP IRA FBO Norman H. Pessin
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
	(a)  þ
3	SEC USE ONLY
4	SOURCE OF FUNDS
	PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States

NUMBER OF SHARES	7	SOLE VOTING POWER
BENEFICIALLY		449,770
OWNED BY EACH	8	SHARED VOTING POWER
REPORTING
PERSON WITH	9	SOLE DISPOSITIVE POWER
		449,770
	10	SHARED DISPOSITIVE POWER

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	449,770
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	1) 4.8%
14	TYPE OF REPORTING PERSON*
	IN

---

PAGE 3

CUSIP No. 163572100

Schedule 13D

---

PAGE 4

CUSIP No.  163572100

Schedule 13D

Item 1.

Security and Issuer

This Schedule 13D relates to the common stock, $0.01 par value (the "Common Stock"), of Chembio Diagnostics, Inc. (the "Issuer"),whose principal executive offices are located at 3661 Horseblock Road, Medford, NY 11763

Item 2.

Identity and Background

This Schedule 13D is being filed by and for Norman H. Pessin and Sandra F. Pessin (each a “Reporting Person”)Certain information with respect to each Reporting Person is set forth below:

 

Name and Address:	1) Norman H. Pessin
	366 Madison Avenue,
	14th Floor
	New York, NY  10017
	2) Sandra F. Pessin
	366 Madison Avenue,
	14th Floor
	New York, NY  10017
Principal Occupation:	1) Retired
	2) Housewife
Criminal convictions:	1) None
	2) None
Civil proceedings:	1) None
	2) None
Citizenship:	1) United States
	2) United States

 

Item 3.

The aggregate purchase price of the 449,770 shares of common stock owned by SEP IRA F/B/O Norman H. Pessin is approximately $2,069,072 including brokerage commissions.  The shares of common stock owned by SEP IRA F/B/O Norman H. Pessin were acquired with personal funds.  The aggregate purchase price of the 36,921 shares of common stock owned by Sandra F. Pessin is approximately $130,477, including brokerage commissions.  The shares of common stock owned by Sandra F. Pessin were acquired with personal funds.

---

PAGE 5

CUSIP No.  163572100

 

Item 4.

Purposes of the Transactions

The Reporting Person originally purchased the Shares based on the belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity.  Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

The Reporting Person intends to review their investment in the Issuer on a continuing basis.  Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to its investment in the Issuer as they deem appropriate including, without limitation, communications with management and the Board of Directors of the Issuer, engaging in discussions with third parties about the Issuer, making proposals to the Issuer concerning changes to the capitalization or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

Item 5.

Interest in Securities of the Issuer

 

SEP IRA F/B/O Norman H. Pessin owns 449,770 shares of common stock of the issuer, constituting 4.8% of the outstanding shares thereof.  Sandra F. Pessin owns 36,921 shares of common stock of the issuer, constituting 0.3% of the outstanding shares thereof.

---

PAGE 6

CUSIP No.  163572100

Item 6.

Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

None.

Item 7.

Material to Be Filed as Exhibits

None.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 20, 2013

---